SC Mosunetuzumab Exhibits Response Durability in Follicular Lymphoma

At the European Hematology Association (EHA) 2026 Congress, Emmanuel Bachy, MD, PhD, presented data from a study evaluating the efficacy and the safety profile of subcutaneous mosunetuzumab (Lunsumio VELO) for the treatment of 43 patients with previously untreated follicular lymphoma meeting high tumor burden criteria.¹

According to Bachy, the results were noteworthy, with the agent demonstrating an overall response rate (ORR) of 90% and a complete response (CR) rate of 88%. When benchmarked against historical data from the phase 3 GALLIUM study (NCT01332968), in which conventional immunochemotherapy achieved a 70% to 75% complete metabolic response (CMR) rate, these findings represent a potential therapeutic advancement.² With a median follow-up of 30 months, the study demonstrated high durability, with a 2-year duration of response rate exceeding 90%.

Coupled with high progression-free survival (PFS) and overall survival (OS) rates and only a single recorded death, Bachy suggested that these results could offer a highly promising strategy for this patient population, suggesting that this intervention may effectively redefine standards of care for high-burden follicular lymphoma.

Transcript:

We presented the primary [end point] of the study, which was both the efficacy and the safety. Regarding the efficacy features, the results were very impressive. The overall response rate was 90% in the 43 patients who were enrolled in the study, and the complete response rate was [88%]. Just as a reminder, if we make a comparison—it’s historical—in the GALLIUM study with conventional immunochemotherapy, we basically reached 70% to 75% of CMR; here, we got an [88%] CR rate, so very high.

The median follow-up is still quite short—it’s 30 months—but durable overall response and durable CR were observed, with a 2-year response duration of more than 90% as well as the duration of [CR]. Regarding the PFS and the OS, they were also very high with a high rate of 2-year PFS and OS. There was only 1 death throughout the study among the 43 patients, so very good results in this follicular lymphoma patient population with high tumor burden criteria.

References

1. Bachy E, Morschhauser F, Eyre TA, et al. Safety and efficacy of subcutaneous mosunetuzumab plus lenalidomide induction therapy followed by mosunetuzumab maintenance in previously untreated follicular lymphoma. Presented at: European Hematology Association 2026 Congress; June 11-14, 2026; Stockholm, Sweden. Abstract S226.
2. Townsend W, Hiddemann W, Buske C, et al. Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study. Hemasphere. 2023:7(7):e919. doi:10.1097/HS9.0000000000000919